In the rapidly evolving landscape of biotechnology, the as1411 peptide—often referred to in scientific literature as a G-rich DNA aptamer—has emerged as a focal point for researchers exploring targeted molecular interactions. While many casual observers encounter this term through various online forums, it is essential to understand its technical classification and the nature of its development to apprec 作者：JE Rosenberg·2013·被引用次数：471—AS1411 has shown antitumour activity in patients with metastatic RCCin a phase I study in patients with solid tumors. At doses ranging from 1 to 40 mg/kg/day iate why it remains a subject of intense academic study.
What is AS1411?
At its core, AS1411 is defined as a synthetic, quadruplex-forming, nuclease-resistant DNA oligonucleotide aptamer. Unlike conventional proteins, this 26-mer G-rich DNA oligonucleotide is engineered to fold into complex structures known as G-quadruplexes. Because AS1411 is a G-rich DNA aptamer, it possesses a unique ability to recognize and bind to specific proteins—most notably nucleolin, which is often found at higher concentrations on the surface of certain cells.
From a structural perspective, AS1411 is a guanosine-rich oligonucleotide aptamer that has garnered significant attention due to its stability and specificity. My personal interest in this molecule began when reviewing how researchers utilize it as a targeting ligand. The fact that AS1411 is internalized by cells upon binding to its target makes it a fascinating candidate for those studying intracellular delivery A Magnetic T7 Peptide&AS1411 Aptamer-Modified mechanisms.
Innovative Applications and Delivery Systems
The utility of this molecule has expanded beyond simple binding. Researchers are now integrating it into complex delivery platforms. For instance, the magnetic T7 peptide & AS1411 aptamer-modified microemulsion represents a sophisticated approach to localized delivery. By combining the targeting pr 作者：EM Reyes-Reyes·2010·被引用次数：456—AS1411 is a first-in-class anticancer agent, currently in Phase II clinical trials. It is a quadruplex-forming oligodeoxynucleotide that binds to nucleolin ecision of the as1411 peptide with other functional motifs, scientists are creating hybrid systems designed to navigate biological environments with higher accuracy.
Some of the most compelling developments include:
* Nanosphere AS1411-functionalized delivery nanosystems for targeted Conjugation: Studies involving AS1411 aptamer-conjugated nanospheres (typically ranging from 100–300 nm) demonstrate how we can package payloads to These results indicated that thispeptide-AS1411coassembled nanoparticle might be satisfyingly stable in protein rich and DNA enzyme conditions improve their transport.
* Coassembly Techniques: The peptide-AS1411 coassembly nanocarrier is another area of interest. These structures are designed to be stable even in challenging, protein-rich conditions, which is a significant hurdle in molecular research.
* Targeted Nanoconjugates: The development of AS1411-PGG-PTX nanoconjugates highlights how these aptamers can be linked to other structures to enhance their performance in experimental models.
Why AS1411 Remains a Key Entity in Research
The history of this molecule is extensive. As a first-in-class anticancer agent, it has been the subject of numerous clinical investigations, including Phase I and Phase II trials. In these settings, AS-1411 is the first oligodeoxynucleotide aptamer to reach phase I and II clinical trials, marking a milestone in the development of synthetic oligonucleotides.
Historically, AS1411 has shown antitumour activity in patients with metastatic RCC (renal cell carcinoma) during early-stage trials, and it is currently being tested as an anticanc AS 1411 inhibits tumor cell proliferationby affecting the activity of nucleoprotein-containing complexes and can be used as a carrier to precisely deliver er agent in various contexts to refine its efficacy. The consensus in the field is that AS1411 inhibits tumor cell proliferation by disrupting the activity of nucleoprotein-containing complexes, which is why it has been widely used for cancer therapy and diagnosis.
Personal Observations on Future Trends
From my perspective as an enthusiast of molecular biology, the Discovery and development of the G-rich oligonucleotide most exciting aspect of AS1411 is a G-rich DNA oligonucleotide is its adaptability. Because it is a 26-mer G-rich DNA oligonucleotide, it is relatively easy to modify with lipids or other polymers to adjust its kinetic properties.
Whether it is being used to develop new diagnostic tools or as a precision vehicle for delivery s AS 1411 (AGRO-100) | Oligonucleotide Aptamer ystems, the as1411 peptide continues to be a cornerstone of modern bio-nanotechnology. As research progresses, we are likely to see even more innovative uses for these G-quadruplex structures, pushing the boundaries of what is possible in targeted molecular science.
*Disclaimer: This article is for informational purposes only and describes scientific research and laboratory developments. It does not provide medical advice, diagnosis, or treatment recommendations.*